Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin

Figures & data

Table 1 Commonly used oral antidiabetic agents and their possible use in several stages of renal impairment

	Creatinine clearance (mL/min)
	30–49	15–29	<15 (dialysis)
Metformin	–	–	–
Sulfonylureas	Often dose reduction necessary	–	–
SGLT-2 inhibitors	Loss of efficacy with lower eGFR	–	–
Repaglinide			Use with caution
Nateglinide		Dose reduction
α-glucosidase inhibitors		<25 mL/min contraindicated	–
Pioglitazone		<4 mL/min contraindicated
Sitagliptin (dose)	1×50 mg/day	1×25 mg/day	1×25 mg/day
Vildagliptin (dose)	1×50 mg/day	1×50 mg/day	1×50 mg/day dialysis: with caution
Saxagliptin (dose)	1×2.5 mg/day	1×2.5 mg/day with caution	Not recommended
Linagliptin (dose)	1×5 mg/day	1×5 mg/day	1×5 mg/day

Abbreviations: eGFR, estimated glomerular filtration rate; SGLT-2, sodium-glucose-transporter-2.